## What is claimed is:

## 1. A compound of formula I

Wherein

R<sub>1</sub> is selected from a)

R<sub>2</sub> is lower alkyl or hydrogen

R<sub>3</sub> is OH or hydrogen;

Z is O, C or -Z- is a bond between the two binding carbon atoms;

is a single or double bond between C2 and C3;

or salts thereof;

with the proviso that when R1 is a, R3 is hydrogen and that when R1 is b, Z is O or a bond, and R2 is methyl R3 is not OH.

## 2. A compound of formula I according to claim 1, wherein

R<sub>1</sub> is

R<sub>2</sub> is lower alkyl preferably methyl

R₃ is hydrogen;

Z is O or -Z- is a bond between the two binding carbon atoms;

is a single bond;

or salts thereof.

## 3. A compound of formula I according to claim 1, wherein

HC C N CH<sub>3</sub>

$$R_1 \text{ is}$$

R<sub>2</sub> is lower alkyl or hydrogen

R<sub>3</sub> is OH or hydrogen;

Z is O, C or -Z- is a bond between the two binding carbon atoms;

is a single or double bond;

or salts thereof;

with the proviso that when R2 is methyl and Z is O or a bond R3 is not OH.

4. A compound of formula I according to claim 1 selected from,

(Z)-(7R,8S,9S,16S)-8-Hydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-methyl-2-(2-methyl-thiazol-4-yl)-vinyl]-oxacyclohexadec-13-ene-2,6-dione;

(1S,3S,10R,11S,12S,16R)-11-Hydroxy-8,8,10,12,16-pentamethyl-3-[(*E*)-1-methyl-2-(2-methyl-thiazol-4-yl)-vinyl]-4,17-dioxa-bicyclo[14.1.0]heptadecane-5,9-dione;

16-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-8-hydroxy-5,5,7,9-tetramethyloxacyclohexadec-13-ene-2,6-dione;

3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-11-hydroxy-8,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(Z)-(7R,8S,9S,16S)-16-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-8-hydroxy-5,5,7,9,13-pentamethyl-oxacyclohexadec-13-ene-2,6-dione;

(1S,3S,10R,11S,12S,16R)-3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-11-hydroxy-8,8,10,12,16-pentamethyl-4,17-dioxa-bicyclo[14.1.0]heptadecane-5,9-dione;

(*E*)-(7R,8S,9S,16S)-16-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-8-hydroxy -5,5,7,9-tetramethyl-oxacyclohexadec-13-ene-2,6-dione;

(1S,3S,10R,11S,12S,16S)-3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-11-hydroxy-8,8,10,12-tetramethyl-4,17-dioxa-bicyclo[14.1.0]heptadecane-5,9-dione;

- 16-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-4,8-dihydroxy-5,5,7,9-tetramethyloxacyclohexadec-13-ene-2,6-dione;
- 3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-7,11-dihydroxy-8,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
- (*E*)-(4S,7R,8S,9S,16S)-16-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-4,8-dihydroxy-5,5,7,9-tetramethyl-oxacyclohexadec-13-ene-2,6-dione;
- (1S,3S,7S,10R,11S,12S,16S)-3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-7,11-dihydroxy-8,8,10,12-tetramethyl-4,17-dioxa-bicyclo[14.1.0]heptadecane-5,9-dione;
- (3E,13E)-(7R,8S,9S,16S)-16-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-8-hydroxy-5,5,7,9-tetramethyl-oxacyclohexadeca-3,13-diene-2,6-dione;
- (E)-(1S,3S,10R,11S,12S,16S)-3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-11-hydroxy-
- 8,8,10,12-tetramethyl-4,17-dioxa-bicyclo[14.1.0]heptadec-6-ene-5,9-dione;
- 3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-7,11-dihydroxy-8,8,10,12-tetramethyl-4-oxa-bicyclo[14.1.0]heptadecane-5,9-dione;and
- (1S,3S,7S,10R,11S,12S,16R)-3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-7,11-dihydroxy-8,8,10,12-tetramethyl-4-oxa-bicyclo[14.1.0]heptadecane-5,9-dione
- 5. A pharmaceutical composition, comprising a compound of formula I, or a salt thereof, provided that salt-forming groups are present, according to one of claims 1 to 4, and one or more pharmaceutically acceptable carriers.
- 6. A compound of formula I according to one of claims 1 to 4, for use in a process for the diagnostic or therapeutic treatment of humans.
- 7. Use of a compound of formula I according to one of claims 1 to 4, for the preparation of a pharmaceutical product for the treatment of a tumour disease.
- 8. Use of a compound of formula I according to one of claims 1 to 4, as a pharmaceutical.
- 9. Process for the preparation of a compound of formula I according to claim 1, characterised in that a compound of formula I may be prepared by ring closure of a compound of formula III

TBSO 
$$R_2$$
  $R_1$   $O$   $OH$   $OH$   $R_3$   $OH$ 

followed by deprotection steps where necessary, wherein

R1, R2 and R3 have the meaning defined in claim 1.